Results of SCT for adults with ALL (selected studies)
| Study . | Population . | Donor . | N . | OS (%) . | LFS (%) . | RI (%) . | TRM (%) . |
|---|---|---|---|---|---|---|---|
| Nishiwaki et al, 201373 | Ph− in CR1 | MSD | 388 | 65 (4 y) | 62 (3 y) | 25 (3 y) | 13 (3 y) |
| URD | 434 | 64 (4 y) | 61 (3 y) | 17 (3 y) | 22 (3 y) | ||
| Cord blood | 95 | 57 (4 y) | 51 (3 y) | 22 (3 y) | 27 (3 y) | ||
| Ph− in CR > 1 | MSD | 89 | 47 (4 y) | 48 (3 y) | 31 (3 y) | 21 (3 y) | |
| URD | 158 | 39 (4 y) | 38 (3 y) | 26 (3 y) | 36 (3 y) | ||
| Cord blood | 53 | 48 (4 y) | 44 (3 y) | 29 (3 y) | 27 (3 y) | ||
| Giebel et al, 201670 | Ph+ and Ph−, CR1 | MSD | 252 | 71 (2 y) | 61 (2 y) | 26 (2 y) | 13 (2 y) |
| URD | 310 | 67 (2 y) | 60 (2 y) | 19 (2 y) | 21 (2 y) | ||
| Cahu et al, 201674 | T-ALL in CR1 | MSD+URD | 414 | 54 (5 y) | 51 (5 y) | — | — |
| T-ALL in CR2 | 93 | 37 (5 y) | 33 (5 y) | — | — | ||
| T-ALL in CR > 2 or active disease | 94 | 12 (5 y) | 9 (5 y) | — | — | ||
| Brissot et al, 201575 | Ph+ in CR1 | MSD | 234 | 45 (5 y) | 36 (5 y) | 43 (5 y) | 20 (5 y) |
| URD | 249 | 47 (5 y) | 40 (5 y) | 30 (5 y) | 30 (5 y) | ||
| Giebel et al, 201876 | Ph+ in molecular CR1 | MSD | 255 | 70 (2 y) | 55 (2 y) | 28 (2 y) | 18 (2 y) |
| URD | 247 | 69 (2 y) | 60 (2 y) | 19 (2 y) | 22 (2 y) | ||
| Autologous | 67 | 70 (2 y) | 52 (2 y) | 47 (2 y) | 2 (2 y) | ||
| Pavlu et al, 201777 | Ph+ and Ph−, primary induction failure∗ | Various | 86 | 23 (5 y) | 17 (5 y) | 54 (5 y) | 29 (5 y) |
| Santoro et al, 202078 | Ph+ and Ph− in CR1 | Matched URD | 809 | 62 (3 y) | 53 (3 y) | 28 (3 y) | 19 (3 y) |
| Mismatched URD | 289 | 62 (3 y) | 55 (3 y) | 25 (3 y) | 20 (3 y) | ||
| Haploidentical† | 136 | 54 (3 y) | 49 (3 y) | 28 (3 y) | 23 (3 y) | ||
| Nagler et al, 202179 | Ph+ and Ph− in CR1 or CR2 | MSD | 1891 | 67 (2 y) | 55 (2 y) | 32 (2 y) | 13 (2 y) |
| Haploidentical† | 413 | 59 (2 y) | 51 (2 y) | 26 (2 y) | 23 (2 y) | ||
| Beelen et al, 202280 | Ph−, HR, CR1, prospective trial | MSD | 176 | 59 (5 y) | 56 (5 y) | 23 (5 y) | 21 (5 y) |
| URD | 366 | 58 (5 y) | 55 (5 y) | 25(5 y) | 20 (5 y) | ||
| Marks et al, 202281 | Unfit for myeloablative conditioning, CR1 | MSD/URD | 249 | 55 (4 y) | 47 (4 y) | 34 (4 y) | 20 (4 y) |
| Study . | Population . | Donor . | N . | OS (%) . | LFS (%) . | RI (%) . | TRM (%) . |
|---|---|---|---|---|---|---|---|
| Nishiwaki et al, 201373 | Ph− in CR1 | MSD | 388 | 65 (4 y) | 62 (3 y) | 25 (3 y) | 13 (3 y) |
| URD | 434 | 64 (4 y) | 61 (3 y) | 17 (3 y) | 22 (3 y) | ||
| Cord blood | 95 | 57 (4 y) | 51 (3 y) | 22 (3 y) | 27 (3 y) | ||
| Ph− in CR > 1 | MSD | 89 | 47 (4 y) | 48 (3 y) | 31 (3 y) | 21 (3 y) | |
| URD | 158 | 39 (4 y) | 38 (3 y) | 26 (3 y) | 36 (3 y) | ||
| Cord blood | 53 | 48 (4 y) | 44 (3 y) | 29 (3 y) | 27 (3 y) | ||
| Giebel et al, 201670 | Ph+ and Ph−, CR1 | MSD | 252 | 71 (2 y) | 61 (2 y) | 26 (2 y) | 13 (2 y) |
| URD | 310 | 67 (2 y) | 60 (2 y) | 19 (2 y) | 21 (2 y) | ||
| Cahu et al, 201674 | T-ALL in CR1 | MSD+URD | 414 | 54 (5 y) | 51 (5 y) | — | — |
| T-ALL in CR2 | 93 | 37 (5 y) | 33 (5 y) | — | — | ||
| T-ALL in CR > 2 or active disease | 94 | 12 (5 y) | 9 (5 y) | — | — | ||
| Brissot et al, 201575 | Ph+ in CR1 | MSD | 234 | 45 (5 y) | 36 (5 y) | 43 (5 y) | 20 (5 y) |
| URD | 249 | 47 (5 y) | 40 (5 y) | 30 (5 y) | 30 (5 y) | ||
| Giebel et al, 201876 | Ph+ in molecular CR1 | MSD | 255 | 70 (2 y) | 55 (2 y) | 28 (2 y) | 18 (2 y) |
| URD | 247 | 69 (2 y) | 60 (2 y) | 19 (2 y) | 22 (2 y) | ||
| Autologous | 67 | 70 (2 y) | 52 (2 y) | 47 (2 y) | 2 (2 y) | ||
| Pavlu et al, 201777 | Ph+ and Ph−, primary induction failure∗ | Various | 86 | 23 (5 y) | 17 (5 y) | 54 (5 y) | 29 (5 y) |
| Santoro et al, 202078 | Ph+ and Ph− in CR1 | Matched URD | 809 | 62 (3 y) | 53 (3 y) | 28 (3 y) | 19 (3 y) |
| Mismatched URD | 289 | 62 (3 y) | 55 (3 y) | 25 (3 y) | 20 (3 y) | ||
| Haploidentical† | 136 | 54 (3 y) | 49 (3 y) | 28 (3 y) | 23 (3 y) | ||
| Nagler et al, 202179 | Ph+ and Ph− in CR1 or CR2 | MSD | 1891 | 67 (2 y) | 55 (2 y) | 32 (2 y) | 13 (2 y) |
| Haploidentical† | 413 | 59 (2 y) | 51 (2 y) | 26 (2 y) | 23 (2 y) | ||
| Beelen et al, 202280 | Ph−, HR, CR1, prospective trial | MSD | 176 | 59 (5 y) | 56 (5 y) | 23 (5 y) | 21 (5 y) |
| URD | 366 | 58 (5 y) | 55 (5 y) | 25(5 y) | 20 (5 y) | ||
| Marks et al, 202281 | Unfit for myeloablative conditioning, CR1 | MSD/URD | 249 | 55 (4 y) | 47 (4 y) | 34 (4 y) | 20 (4 y) |